ARE YOU ELIGIBLE FOR THE **SPYRAL HTN CLINICAL TRIAL?**

To be eligible for the SPYRAL HTN Clinical Trial Program, patients must be between the ages of 20 and 80 and have uncontrolled hypertension, with readings of:

- Systolic blood pressure (upper number) reading between 150 - 180 mm Hg.
- Diastolic blood pressure (lower number) reading above 90 mm Hg.
- If deemed eligible, participation is voluntary. Potential risks and benefits of being a participant in this clinical trial program should be discussed with your physician.

WHAT RESPONSIBILITIES DO **PATIENTS IN THE TRIAL HAVE?**

If you are eligible to participate in the SPYRAL HTN Clinical Trial Program, you will be required to:

- Attend regular clinic check-ups with your doctor.
- Wear a blood pressure monitoring cuff continuously for up to 24 hours at a time.
- You may also be required to consistently and reliably take your blood pressure medication for the duration of the study (although some patients may be able to stop taking their medication completely).

SPEAK WITH YOUR DOCTOR TO LEARN MORE ABOUT **RENAL DENERVATION AND THE PRE-SCREENING STEPS.**

References:
1. Hypertension. 2nd ed., H.R. Black, W.J. Elliott, 2013. Elsevier publishing. Pp 13-16.

INTRODUCING AN INVESTIGATIONAL TREATMENT FOR HIGH BLOOD PRESSURE

SPYRAL HTN GLOBAL CLINICAL TRIAL PROGRAM

INFORMATION **FOR PATIENTS**

Medtronic
Further, Together

HOW THE RENAL NERVES INFLUENCE **HIGH BLOOD PRESSURE**[1]

Research has shown that the kidneys play an important role in managing blood pressure. Sometimes, however, the nerves that control the kidney become over-active. This can cause the blood pressure to rise, leading to high blood pressure, also known as hypertension.

Knowing this, researchers developed an innovative procedure using an investigational device that uses energy to adjust the nerves that control the kidneys.



AN INNOVATIVE APPROACH **TO LOWER BLOOD PRESSURE**

Renal denervation is an investigational therapy that consists of a novel, minimally invasive procedure. Using active energy, overactive nerves that lead to the kidneys are adjusted from within each artery, potentially helping to balance overactive signaling. This procedure can be performed in a single session by inserting a tiny tube into the arteries leading to the kidneys. Following treatment, the device is removed. The single procedure offers the possibility of sustained blood pressure reduction.

THE SPYRAL HTN GLOBAL **CLINICAL TRIAL PROGRAM**

The purpose of the SPYRAL HTN Global Clinical Trial Program is to provide information about the **safety and efficacy** of the investigational Symplicity Spyral™ catheter and the Symplicity G3™ generator to help reduce blood pressure in patients whose blood pressure is not controlled despite lifestyle changes.



Guide catheter inserted into artery



Renal Denervation Symplicity Spyral™ catheter delivers energy to artery



Guide and Symplicity Spyral™ catheter repositioned & treatment repeated into other artery



All devices are removed once treatment is delivered